Laboratory characteristics |
Laboratory
characteristics |
Laboratory characteristics |
Laboratory characteristics |
Laboratory
characteristics |
Hemoglobin (g/dl) (n=738) |
13.5 ± 2.01 |
13.2 ± 1.77 |
12.2 ±
1.98***
|
<0.001 |
Blood urea nitrogen (n=621) |
21.0 ± 11.1 |
28.1 ±
14.7***
|
40.2 ± 21.1***
|
<0.001 |
Creatinine |
0.90 ± 0.16 |
1.00 ± 0.23**
|
1.71 ± 0.81***
|
<0.001 |
GFR-MDRD |
91.8 ± 23.7 |
79.7 ± 23.5***
|
46.2 ± 21.5***
|
<0.001 |
BNP (n=44) |
27.9 (20.4-64.2) |
70.7 (33.3-116.0) |
30.3
(21.5-40.9) |
0.09 |
NT-proBNP (n=211) |
941.0 (498.0-2660.0) |
1537.0
(634.0-4850.0) |
2798.0 (560.0-5310.0) *
|
0.03 |
Sodium (n=739) |
138.0 ± 4.0 |
138.0 ± 3.9 |
137.0 ± 6.0 |
0.06 |
Albumin (n=426) |
3.94 ± 0.60 |
3.92 ± 0.69 |
3.74 ±
0.70***
|
<0.001 |
Medications |
Medications |
Medications |
Medications |
Medications |
ACE inhibitors (%) |
171 (68.7%) |
162 (65.1%) |
160
(64.0%) |
0.51 |
Angiotensin receptor blockers (%) |
82 (32.9%) |
84 (33.7%) |
101 (40.4%) |
0.16 |
Beta blockers (%) |
224 (90.0%) |
229 (92.0%) |
229 (91.6%) |
0.70 |
Mineralocorticoid receptor blockers (%) |
149 (59.8%) |
160
(64.3%) |
140 (56.0%) |
0.17 |
Diuretics (%) |
96 (38.6%) |
114 (46.0%) |
113 (46.3%) |
0.14 |
Digoxin (%) |
22 (8.8%) |
39 (15.7%) |
28 (11.5%) |
0.06 |
Outcomes |
Outcomes |
Outcomes |
Outcomes |
Outcomes |
At least one hospitalization during follow up (%) (n=670) |
112 (51.1%) |
137 (60.1%) |
151 (67.7%)***
|
0.002 |
Total number of hospitalizations during follow up (%) (n=668) |
1.00 (0.00-1.00) |
1.00 (0.00-2.00) |
1.00
(0.00-2.25)***
|
<0.001 |
All-cause mortality (%) |
27 (10.8%) |
40 (16.1%) |
75
(30.0%) |
<0.001 |